A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.

Ann C. Childress,Andrew J. Cutler,Andrea Marraffino,Mary Ann McDonnell,John M. Turnbow,Matthew Brams,Norberto J. DeSousa,Bev Incledon,Floyd R. Sallee,Sharon B. Wigal

A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.

2019

Ann C. Childress
Andrew J. Cutler
Andrea Marraffino
Mary Ann McDonnell
John M. Turnbow
Matthew Brams
Norberto J. DeSousa
Bev Incledon
Floyd R. Sallee
Sharon B. Wigal

Abstract Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon awakening and l...

Keywords:

Psychology
Attention deficit hyperactivity disorder
Methylphenidate
Therapeutic effect
Upon Awakening
Placebo-controlled study
Psychiatry
extended release
double blind
functional impairment
Pediatrics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations